Hands-on demonstrations will include the
company's first single-use flexible ureteroscope
CENTER
VALLEY, Pa., April 30,
2024 /PRNewswire/ -- Olympus, a global medical
technology company committed to making people's lives healthier,
safer and more fulfilling, will highlight a diverse urology
portfolio that can help physicians treat bladder cancer, urinary
stones and enlarged prostate during this year's American Urological
Association (AUA) annual meeting May
3-6 in San Antonio.
Olympus will feature the recently FDA-cleared RenaFlex™
single-use flexible ureteroscope system, the company's first
single-use ureteroscope, and the ESG-410™ Surgical Energy Platform
which supports procedural approaches and efficiencies in the
treatment of NMIBC (non-muscle-invasive bladder cancer), benign
prostatic hyperplasia (BPH), as well as a wide variety of open and
laparoscopic procedures.
As the exclusive AUA2024 clinical practice guideline sponsor,
Olympus will provide 2,500 copies of the AUA2024
Guidelines-At-A-Glance compendium books, which include the
recommendation of Narrow Band Imaging™ (NBI™) technology for the
diagnosis and treatment of NMIBC and the iTind™ procedure for the
management of lower urinary tract symptoms attributed to BPH. The
iTind procedure is reflected in the new procedure category,
Temporary Implanted Prostatic Devices (TIPD).1
Stone management
The RenaFlex single-use flexible ureteroscope is intended to be
used to visualize organs, cavities and canals in the urinary tract.
It can also be used with endoscopic accessories to perform various
diagnostic and therapeutic procedures in the urinary
tract.2 Visitors to the Olympus booth will have an
opportunity for a hands-on skills challenge using the RenaFlex
ureteroscope, which will be available in limited market launch in
2024.
The RenaFlex Single-use Ureteroscope works in combination with
the compatible CV-S1 Video System Center for flexible single-use.
For safe and proper use, follow the manufacturer's instructions for
use, handling, and operating of the RenaFlex Single-use
Ureteroscope and the CV-S1 Video System Center. If used or handled
in an improper manner, there is a risk of patient and/or operator
injuries, burns, infections, bleeding, and/or perforation, and/or
equipment damage.
The RenaFlex system is part of a larger stone management
portfolio of products that allow physicians to confidently approach
every patient or procedure at any site of care. Included in that
portfolio is the SOLTIVE™ Premium SuperPulsed Laser System (SOLTIVE
Laser System). The SOLTIVE System's thulium fiber laser (TFL)
technology allows physicians to dust kidney stones more quickly
than advanced post-modulation Holmium:YAG technology.3
The SOLTIVE System will also be available for hands-on
demonstrations.
The SOLTIVE SuperPulsed Laser, powered by a novel energy
source, is capable of dusting stones in half the time and
fragmenting stones relentlessly with virtually no retropulsion. For
effective dusting and fragmentation, the tip of the laser fiber
should be directly in contact with the stone. Continuous irrigation
should be used to wash away stone fragments and to provide cooling
of the treatment site. The use of higher power settings should be
avoided, especially when the fiber tip is in close proximity to the
ureteral wall, as perforation of the ureter may result.
As with non-laser surgery, the possibility of complications and
adverse events, such as chills, fever, edema, hemorrhage,
inflammation, tissue necrosis, or infection may occur following
treatment. In extreme cases, death may occur due to procedural
complications, concurrent illness, or laser application. As with
any conventional surgery, acute pain may occur immediately
following laser therapy and may persist for as long as 48
hours.4
Drs. Ahmed Ghazi and Naeem Bhojani will offer "Ask the Experts"
lectures regarding their experiences with the SOLTIVE System along
with a "Tech Talk" by Dr. Mantu
Gupta, who will highlight the versatility of the laser
platform.5
Bladder Cancer
The ESG-410 Surgical Energy Platform supports procedural
approaches and efficiencies for the treatment of NMIBC. It is
equipped with enhanced capacitors that allow for better plasma
stability during ignition,6 and it powers the five modes
of commonly used energy: monopolar, bipolar, advanced bipolar,
ultrasonic and hybrid energy for use in endoscopic, laparoscopic
and open procedures. The ESG-410 Surgical Energy Platform can be
used in concert with Olympus' NBI™ technology that enhances
visual observation of mucosal and vascular patterns by utilizing
specific blue and green wavelengths absorbed by
hemoglobin.7 NBI is not intended to replace
histopathological sampling as a means of diagnosis.
Recent data shows that the use of NBI technology with NMIBC
patients led to a 37% less likelihood of recurrence over 12-35
months.8 Monitoring bladder cancer is critical. The
American Cancer Society reports that bladder cancer has one of the
highest recurrence rates9 with patients typically
undergoing cystoscopy about every three months for years after
treatment.10
BPH
Olympus offers a variety of minimally invasive and surgical
treatment options to treat men with an enlarged prostate (BPH). The
iTind™ procedure is a novel minimally invasive BPH treatment option
that involves the placement of a temporarily implanted nitinol
device that reshapes the prostatic urethra without burning or
cutting out the prostate. It remains in place for five to seven
days while the patient is at home. Upon physician removal, patients
experience rapid and effective relief of their
symptoms.11
The iTind device is indicated in men age 50 and above.
Implantation of the iTind device may cause pelvic discomfort, blood
in urine, painful or urgent urination. In rare cases, the iTind
device may cause urinary tract infection or a sudden difficulty to
urinate.
Olympus will host an iTind procedure "Tech Talk" to discuss how
the iTind device was invented, how it works and which patients are
ideal for treatment. Drs. Naveen
Kella and Rahul Mehan will
also offer "Ask the Experts" lectures in the Olympus booth
regarding their experiences with the procedure.12
The ESG-410™ Surgical Energy Platform supports options for the
treatment of BPH by providing an array of resection loops and
vaporization buttons. The ESG-410 Surgical Energy Platform offers
enhanced procedural efficiency in BPH resections due to faster
tissue removal because of reliable ignition of larger resection
loops.13
The ESG-410 electrosurgical generator, with its accessories and
ancillary equipment, is intended for cutting and coagulation of
tissue in open, laparoscopic and endoscopic surgery and should only
be used by a qualified physician in an adequate medical
environment. Improper use or use of incompatible equipment
with this electrosurgical generator can lead to excessive or
incorrect HF and cause thermal or other injuries for the patient
and/or operator. All plugs must be securely inserted to the
corresponding sockets for proper use. Be aware that if the main
plug is accidentally disconnected during a procedure, the
electrosurgical generator immediately turns off and this can result
in complications for the patient. Please refer to the instructions
for use prior to usage.
For more information about the urological portfolio, visit the
Olympus booth, #311, during AUA or visit the RenaFlex™ system,
ESG-410 Platform, SOLTIVE™ Laser System and iTind™ product
pages for more information.
About Olympus
At Olympus, we are committed to Our
Purpose of making people's lives healthier, safer and more
fulfilling. As a global medical technology company, we partner with
healthcare professionals to provide solutions and services for
early detection, diagnosis and minimally invasive treatment, aiming
to improve patient outcomes by elevating the standard of care in
targeted disease states.
Olympus Corporation of the Americas, a wholly owned subsidiary
of Olympus Corporation, is headquartered in Center Valley, Pennsylvania, USA, and employs
more than 4,500 employees throughout locations in North and
South America. For more
information, visit olympusamerica.com.
1 Sandhu JS, Bixler BR, Dahm P, et al.
« Management of lower urinary tract symptoms attributed to
benign prostatic hyperplasia (BPH): AUA Guideline amendment 2023."
J Urol. 2023;10. doi.org/10.1097/JU.0000000000003698
2 RenaFlex IFU
3 Benchmark study. Comparison of dusting and fragmenting
using the new Super Pulse Thulium Fiber Laser to a 120W Holmium:
YAG laser. AUA 2019. Dr. Ben
Chew
4 For further information please refer to the SOLTIVETM
Laser System IFU • PN001555 1_AE
5 Drs. Ahmed Ghazi,
Naeem Bhojani and Mantu Gupta are paid consultants for Olympus
Corporation of the Americas
6 When compared to the ESG-400 generator. Data on file
02/2023
7 Data on file with Olympus (D00489968)
8 Lai LY, Tafuri SM, Ginier EC, Herrel LA, Dahm P,
Maisch P, Lane GI. "Narrow band imaging versus white light
cystoscopy alone for transurethral resection of non-muscle invasive
bladder cancer." Cochrane Database Syst Rev. 2022 Apr 8;4(4):CD014887. doi:
10.1002/14651858.CD014887.pub2. PMID: 35393644; PMCID:
PMC8990285
9 American Cancer Society, "Cancer Recurrence Rates."
Rev. December 2023
10 American Cancer Society, "Treatment of Bladder
Cancer, by Stage." Rev. December
2023
11 Chughtai, B; Elterman, D; Shore, N; et al. "The
iTind Temporarily Implanted Nitinol Device for the Treatment of
Lower Urinary Tract Symptoms Secondary to Benign Prostatic
Hyperplasia: A Multicenter, Randomized, Controlled Trial." Journal
of Urology, pub. July 2021
12 Drs. Naveen Kella and
Rahul Mehan are paid consultants for
Olympus Corporation of the Americas
13 When compared with competitive generator. Data on
file 02/2023
View original content to download
multimedia:https://www.prnewswire.com/news-releases/olympus-to-highlight-diverse-treatment-portfolio-at-american-urological-association-annual-meeting-302130223.html
SOURCE Olympus Corporation of the Americas